Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor Vaccine
Introduction. No effective treatment has been developed for bone-metastatic breast cancer. We found 3 cases with clinical complete response (cCR) of the bone metastasis and longer overall survival of the retrospectively examined cohort treated comprehensively including autologous formalin-fixed tumo...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | International Journal of Breast Cancer |
| Online Access: | http://dx.doi.org/10.1155/2018/4879406 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849399797864202240 |
|---|---|
| author | Fumito Kuranishi Yuki Imaoka Yuusuke Sumi Yoji Uemae Hiroko Yasuda-Kurihara Takeshi Ishihara Tsubasa Miyazaki Tadao Ohno |
| author_facet | Fumito Kuranishi Yuki Imaoka Yuusuke Sumi Yoji Uemae Hiroko Yasuda-Kurihara Takeshi Ishihara Tsubasa Miyazaki Tadao Ohno |
| author_sort | Fumito Kuranishi |
| collection | DOAJ |
| description | Introduction. No effective treatment has been developed for bone-metastatic breast cancer. We found 3 cases with clinical complete response (cCR) of the bone metastasis and longer overall survival of the retrospectively examined cohort treated comprehensively including autologous formalin-fixed tumor vaccine (AFTV). Patients and Methods. AFTV was prepared individually for each patient from their own formalin-fixed and paraffin-embedded breast cancer tissues. Results. Three patients maintained cCR status of the bone metastasis for 17 months or more. Rate of cCR for 1 year or more appeared to be 15% (3/20) after comprehensive treatments including AFTV. The median overall survival time (60.0 months) and the 3- to 8-year survival rates after diagnosis of bone metastasis were greater than those of historical control cohorts in Japan (1988–2002) and in the nationwide population-based cohort study of Denmark (1999–2007). Conclusion. Bone-metastatic breast cancer may be curable after comprehensive treatments including AFTV, although larger scale clinical trial is required. |
| format | Article |
| id | doaj-art-9cbfee63ad364b988cef2c5c510d1602 |
| institution | Kabale University |
| issn | 2090-3170 2090-3189 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Breast Cancer |
| spelling | doaj-art-9cbfee63ad364b988cef2c5c510d16022025-08-20T03:38:15ZengWileyInternational Journal of Breast Cancer2090-31702090-31892018-01-01201810.1155/2018/48794064879406Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor VaccineFumito Kuranishi0Yuki Imaoka1Yuusuke Sumi2Yoji Uemae3Hiroko Yasuda-Kurihara4Takeshi Ishihara5Tsubasa Miyazaki6Tadao Ohno7Department of Surgery, Innoshima-Ishikai Hospital, Innoshima, Onomichi, Hiroshima 722-2211, JapanDepartment of Surgery, Innoshima-Ishikai Hospital, Innoshima, Onomichi, Hiroshima 722-2211, JapanDepartment of Surgery, Innoshima-Ishikai Hospital, Innoshima, Onomichi, Hiroshima 722-2211, JapanCell-Medicine, Inc., 2-1-6 Sengen, Tsukuba, Ibaraki 305-0074, JapanCell-Medicine, Inc., 2-1-6 Sengen, Tsukuba, Ibaraki 305-0074, JapanCell-Medicine, Inc., 2-1-6 Sengen, Tsukuba, Ibaraki 305-0074, JapanCell-Medicine, Inc., 2-1-6 Sengen, Tsukuba, Ibaraki 305-0074, JapanCell-Medicine, Inc., 2-1-6 Sengen, Tsukuba, Ibaraki 305-0074, JapanIntroduction. No effective treatment has been developed for bone-metastatic breast cancer. We found 3 cases with clinical complete response (cCR) of the bone metastasis and longer overall survival of the retrospectively examined cohort treated comprehensively including autologous formalin-fixed tumor vaccine (AFTV). Patients and Methods. AFTV was prepared individually for each patient from their own formalin-fixed and paraffin-embedded breast cancer tissues. Results. Three patients maintained cCR status of the bone metastasis for 17 months or more. Rate of cCR for 1 year or more appeared to be 15% (3/20) after comprehensive treatments including AFTV. The median overall survival time (60.0 months) and the 3- to 8-year survival rates after diagnosis of bone metastasis were greater than those of historical control cohorts in Japan (1988–2002) and in the nationwide population-based cohort study of Denmark (1999–2007). Conclusion. Bone-metastatic breast cancer may be curable after comprehensive treatments including AFTV, although larger scale clinical trial is required.http://dx.doi.org/10.1155/2018/4879406 |
| spellingShingle | Fumito Kuranishi Yuki Imaoka Yuusuke Sumi Yoji Uemae Hiroko Yasuda-Kurihara Takeshi Ishihara Tsubasa Miyazaki Tadao Ohno Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor Vaccine International Journal of Breast Cancer |
| title | Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor Vaccine |
| title_full | Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor Vaccine |
| title_fullStr | Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor Vaccine |
| title_full_unstemmed | Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor Vaccine |
| title_short | Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor Vaccine |
| title_sort | rate of clinical complete response for 1 year or more in bone metastatic breast cancer after comprehensive treatments including autologous formalin fixed tumor vaccine |
| url | http://dx.doi.org/10.1155/2018/4879406 |
| work_keys_str_mv | AT fumitokuranishi rateofclinicalcompleteresponsefor1yearormoreinbonemetastaticbreastcanceraftercomprehensivetreatmentsincludingautologousformalinfixedtumorvaccine AT yukiimaoka rateofclinicalcompleteresponsefor1yearormoreinbonemetastaticbreastcanceraftercomprehensivetreatmentsincludingautologousformalinfixedtumorvaccine AT yuusukesumi rateofclinicalcompleteresponsefor1yearormoreinbonemetastaticbreastcanceraftercomprehensivetreatmentsincludingautologousformalinfixedtumorvaccine AT yojiuemae rateofclinicalcompleteresponsefor1yearormoreinbonemetastaticbreastcanceraftercomprehensivetreatmentsincludingautologousformalinfixedtumorvaccine AT hirokoyasudakurihara rateofclinicalcompleteresponsefor1yearormoreinbonemetastaticbreastcanceraftercomprehensivetreatmentsincludingautologousformalinfixedtumorvaccine AT takeshiishihara rateofclinicalcompleteresponsefor1yearormoreinbonemetastaticbreastcanceraftercomprehensivetreatmentsincludingautologousformalinfixedtumorvaccine AT tsubasamiyazaki rateofclinicalcompleteresponsefor1yearormoreinbonemetastaticbreastcanceraftercomprehensivetreatmentsincludingautologousformalinfixedtumorvaccine AT tadaoohno rateofclinicalcompleteresponsefor1yearormoreinbonemetastaticbreastcanceraftercomprehensivetreatmentsincludingautologousformalinfixedtumorvaccine |